(RTTNews) - Equillium, Inc., (EQ), a clinical-stage biotechnology company, reported a wider loss in its third quarter compared to last year, mainly due to higher research & development expenses.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.